KEYNOTE-365 cohort c updated results: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients with metastatic Castration-Resistant Prostate Cancer (mCRPC)

KEYNOTE-365 cohort c updated results: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients with metastatic Castration-Resistant Prostate Cancer (mCRPC)

Bibliographic Details
Main Authors: S. Feyerabend, W. Berry, P. Fong, J.M. Piulats, L. Appleman, H. Conter, N. Shore, G. Gravis, B. Laguerre, H. Gurney, M. Retz, E. Romano, L. Mourey, J. De Bono, A. Kam, U. Emmenegger, H. Wu, C. Schloss, C. Poehlein, E.Y. Yu
Format: Article
Language:English
Published: Elsevier 2020-07-01
Series:European Urology Open Science
Online Access:http://www.sciencedirect.com/science/article/pii/S2666168320331657

Internet

http://www.sciencedirect.com/science/article/pii/S2666168320331657

Similar Items